Blackrock Neurotech is an Invasive Cortical Implants company founded in 2008 and based in Salt Lake City, United States. It has raised $200M in total funding, most recently a Strategic Investment in 2024 at a $350M valuation.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Apr 29, 2024 | Acquired | $200M | $350M | Tether |
| May 19, 2021 | Series A | — | — |
| re.Mind Capital |
Intracortical microelectrode array — the gold-standard research implant for invasive BCI — featuring up to 128 silicon penetrating electrodes that record from and stimulate individual neurons simultaneously. Implanted in humans since 2004, it has underpinned landmark BCI demonstrations including robotic-arm control, typed speech, and sensory feedback restoration. Used across dozens of academic institutions and clinical trials worldwide as a research and clinical development platform.
FDA Breakthrough Device-designated clinical BCI system designed for patients with paralysis or limb loss. Decodes motor intent from Utah Array cortical recordings and translates neural signals into control of external devices — cursor, keyboard, mobile device, powered wheelchair, or prosthetic limb — enabling direct brain-to-device communication. Targets motor-complete spinal cord injury and amyotrophic lateral sclerosis populations for functional independence restoration.
No recently verified openings are available right now. The company's careers page has the latest.
View all careers ↗